Abstract
Introduction
Breast cancer survivors are often prescribed medications for at least 5 years to reduce recurrence risk, yet some forego this treatment due to cost. We sought to elucidate the prevalence of this and the factors contributing to it.
Methods
The National Health Interview Survey (NHIS) is a population-based survey, representative of the civilian non-institutionalized US population, administered annually by the CDC. People diagnosed with breast cancer within the past 5 years surveyed in the 2018 NHIS formed the cohort of interest.
Results
Of the 24,858 breast cancer survivors surveyed, representing 244,607,304 in the population, 6.32% stated that they needed a prescription medicine within the past 12 months, but didn’t get it filled because they couldn’t afford it. Of those who had gotten a prescription within the past 12 months, 5.71, 5.94 and 7.48% had either skipped doses, taken less medication than prescribed, or delayed filling a prescription, respectively, to save money. 11.99% of people had done at least one of these, thereby foregoing treatment. On bivariate analyses, factors associated with foregoing treatment included age, race, education, family income, and insurance status (p < 0.001 for all). On multivariable analysis, age, race, family income, and insurance status were all independent predictors of foregoing treatment (p < 0.001 for all); education status was not significant in the model (p = 0.211).
Conclusion
Roughly 12% of breast cancer survivors who are prescribed medications within the first 5 years of their diagnosis will forego treatment due to cost. Family income and insurance status are key modifiable drivers of this.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
AlOmeir OA-O, Patel NA-O, Donyai PA-O (2020) Adherence to adjuvant endocrine therapy among breast cancer survivors: a systematic review and meta-synthesis of the qualitative literature using grounded theory. Support Care Cancer 28(11):5075–5084
Ganz PA, Goodwin PJ (2015) Breast cancer survivorship: where are we today? Adv Exp Med Biol 862(0065–2598 (Print)):1–8
Diaby V, Tawk R, Sanogo V, Xiao H, Montero AJ (2015) A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer. Breast Cancer Res Treat 151(1):27–40
Spring LM, Gupta A, Reynolds KL, Gadd MA, Ellisen LW, Isakoff SJ, Moy B, Bardia A (2016) Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis. JAMA Oncol 2(11):1477–1486
NCCN clinical practice guidelines in oncology: breast cancer. Accessed http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP et al (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28(23):3784–3796
Early Breast Cancer Trialists’ Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Early breast cancer trialists’ collaborative group. Lancet 351(9114):1451–1467
Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW (2012) Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat 134(2):459–478
Farias AJ, Du XL (2017) Association between out-of-pocket costs, race/ethnicity, and adjuvant endocrine therapy adherence among medicare patients with breast cancer. J Clin Oncol 35(1):86–95
Farias AJ, Hansen RN, Zeliadt SB, Ornelas IJ, Li CI, Thompson B (2018) The association between out-of-pocket costs and adherence to adjuvant endocrine therapy among newly diagnosed breast cancer patients. Am J Clin Oncol 41(7):708–715
Chin AL, Bentley JP, Pollom EL (2019) The impact of state parity laws on copayments for and adherence to oral endocrine therapy for breast cancer. Cancer 125(3):374–381
National Center for Health Statistics (2018) 2018 national health interview survey (NHIS) public use data release: survey description. Centers for Disease Control and Prevention, Hyattsville
About the National Health Interview Survey. Accessed https://www.cdc.gov/nchs/nhis/about_nhis.htm
Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, Kwan M, Gomez SL, Neugut AI (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126(2):529–537
Neugut AI, Zhong X, Wright JD, Accordino M, Yang J, Hershman DL (2016) Nonadherence to medications for chronic conditions and nonadherence to adjuvant hormonal therapy in women with breast cancer. JAMA Oncol 2(10):1326–1332
Kennedy J, Morgan S (2006) A cross-national study of prescription nonadherence due to cost: data from the joint Canada-United States survey of health. Clin Ther 28(8):1217–1224
Chung GC, Marottoli RA, Cooney LM, Rhee TA-O (2019) Cost-related medication nonadherence among older adults: findings from a nationally representative sample. J Am Geriatr Soc 67(12):2463
Morgan SA-O, Lee A (2017) Cost-related non-adherence to prescribed medicines among older adults: a cross-sectional analysis of a survey in 11 developed countries. BMJ Open 7(1):e014287
Lee M, Salloum RG (2016) Racial and ethnic disparities in cost-related medication non-adherence among cancer survivors. J Cancer Surviv 10(3):534–544
Ma SA-O, Shepard DS, Ritter GA, Martell RE, Thomas CP (2020) The impact of the introduction of generic aromatase inhibitors on adherence to hormonal therapy over the full course of 5-year treatment for breast cancer. Cancer 126(15):3417–3425
Neuner JM, Kamaraju S, Charlson JA, Wozniak EM, Smith EC, Biggers A, Smallwood AJ, Laud PW, Pezzin LE (2015) The introduction of generic aromatase inhibitors and treatment adherence among medicare D enrollees. J Natl Cancer Inst 107(8):djv130
Ruff P, Al-Sukhun S, Blanchard C, Shulman LN (2016) Access to cancer therapeutics in low- and middle-income countries. Am Soc Clin Oncol Educ Book 36:58–65
Foerster M, Anderson BO, McKenzie F, Galukande M, Anele A, Adisa C, Zietsman A, Schuz J, dos Santos SI, McCormack V (2019) Inequities in breast cancer treatment in sub-Saharan Africa: findings from a prospective multi-country observational study. Breast Cancer Res 21(1):93
Schut FT, Van Bergeijk PAG (1986) International price discrimination: the pharmaceutical industry. World Dev 14(9):1141–1150
Funding
None.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Authors declared that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Zheng, C., Chagpar, A.B. Contribution of cost to treatment nonadherence in the US breast cancer survivors: a population-based analysis. Breast Cancer Res Treat 192, 369–373 (2022). https://doi.org/10.1007/s10549-022-06510-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-022-06510-w